Skip to content

Regenxbio RGNX Return on assets

Return on assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
11.3%-1.2pp
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-7.4%-8.6pp
Biogen logo
BiogenBIIB
4.9%-0.5pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
7.2%+2.5pp
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-83.5%+2,448pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-46.7%+6.0pp

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

Based on trailing twelve months.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's return on assets?
Regenxbio (RGNX) reported return on assets of -69.6% in Q1 2026.
How has Regenxbio's return on assets changed year-over-year?
Regenxbio's return on assets decreased by 147.4% year-over-year, from -28.2% to -69.6%.
What is the long-term trend for Regenxbio's return on assets?
Over 5 years (2020 to 2025), Regenxbio's return on assets has grown at a 18.0% compound annual growth rate (CAGR), from -18.4% to -42.2%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.